科研之友
微信
新浪微博
Facebook
分享链接
摘要
IL-1 is a master cytokine that plays a pivotal role in local and systemic inflammation and is involved in the host response to both physiological and pathological stimuli. The recent development of biological compounds targeting IL-1 activity in vivo has revealed the contribution of this cytokine to a large number of human inflammatory and autoimmune diseases. Nevertheless, these currently used drugs display some disadvantages that limit their use in several IL-1-driven diseases, urging for the identification of more powerful agents. The present article describes the identification of new small peptides displaying IL-1 inhibitory activity and covered by the patent WO2012122985. The experimental work in support of the patent%26apos;s claims is also discussed. Specific attention is paid to the comparison with the original compound from which the peptides were originated: the IL-1 receptor antagonist (IL-1RA) protein. The potential advantages brought about by the present invention as well as the limits documented by the experimental results shown in the patent are also discussed.
- 出版日期2013-7
